Sodium zirconium cyclosilicate increases serum bicarbonate concentrations among patients with hyperkalaemia: exploratory analyses from three randomized, multi-dose, placebo-controlled trials.
hyperkalaemia
potassium
serum bicarbonate
serum urea
sodium zirconium cyclosilicate
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
26 04 2021
26 04 2021
Historique:
received:
11
02
2020
pubmed:
27
6
2020
medline:
23
7
2021
entrez:
27
6
2020
Statut:
ppublish
Résumé
Sodium zirconium cyclosilicate (SZC) binds potassium and ammonium in the gastrointestinal tract. In addition to serum potassium reduction, Phase 2 trial data have shown increased serum bicarbonate with SZC, which may be clinically beneficial because maintaining serum bicarbonate ≥22 mmol/L preserves kidney function. This exploratory analysis examined serum bicarbonate and urea, and urine pH data from three SZC randomized, placebo-controlled Phase 3 studies among patients with hyperkalaemia [ZS-003 (n = 753), HARMONIZE (n = 258) and HARMONIZE-Global (n = 267)]. In all studies, patients received ≤10 g SZC 3 times daily (TID) for 48 h to correct hyperkalaemia, followed by randomization to maintenance therapy with SZC once daily (QD) versus placebo for ≤29 days among those achieving normokalaemia. Significant dose-dependent mean serum bicarbonate increases from baseline of 0.3 to 1.5 mmol/L occurred within 48 h of SZC TID in ZS-003 (all P < 0.05), which occurred regardless of chronic kidney disease (CKD) stage. Similar acute increases in HARMONIZE and HARMONIZE-Global were maintained over 29 days. With highest SZC maintenance doses, patient proportions with serum bicarbonate <22 mmol/L fell from 39.4% at baseline to 4.9% at 29 days (P = 0.005) in HARMONIZE and from 87.9% to 70.1%, (P = 0.006) in HARMONIZE-Global. Path analyses demonstrated that serum urea decreases (but not serum potassium or urine pH changes) were associated with SZC effects on serum bicarbonate. SZC increased serum bicarbonate concentrations and reduced patient proportions with serum bicarbonate <22 mmol/L, likely due to SZC-binding of gastrointestinal ammonium. These SZC-induced serum bicarbonate increases occurred regardless of CKD stage and were sustained during ongoing maintenance therapy.
Sections du résumé
BACKGROUND
Sodium zirconium cyclosilicate (SZC) binds potassium and ammonium in the gastrointestinal tract. In addition to serum potassium reduction, Phase 2 trial data have shown increased serum bicarbonate with SZC, which may be clinically beneficial because maintaining serum bicarbonate ≥22 mmol/L preserves kidney function. This exploratory analysis examined serum bicarbonate and urea, and urine pH data from three SZC randomized, placebo-controlled Phase 3 studies among patients with hyperkalaemia [ZS-003 (n = 753), HARMONIZE (n = 258) and HARMONIZE-Global (n = 267)].
METHODS
In all studies, patients received ≤10 g SZC 3 times daily (TID) for 48 h to correct hyperkalaemia, followed by randomization to maintenance therapy with SZC once daily (QD) versus placebo for ≤29 days among those achieving normokalaemia.
RESULTS
Significant dose-dependent mean serum bicarbonate increases from baseline of 0.3 to 1.5 mmol/L occurred within 48 h of SZC TID in ZS-003 (all P < 0.05), which occurred regardless of chronic kidney disease (CKD) stage. Similar acute increases in HARMONIZE and HARMONIZE-Global were maintained over 29 days. With highest SZC maintenance doses, patient proportions with serum bicarbonate <22 mmol/L fell from 39.4% at baseline to 4.9% at 29 days (P = 0.005) in HARMONIZE and from 87.9% to 70.1%, (P = 0.006) in HARMONIZE-Global. Path analyses demonstrated that serum urea decreases (but not serum potassium or urine pH changes) were associated with SZC effects on serum bicarbonate.
CONCLUSIONS
SZC increased serum bicarbonate concentrations and reduced patient proportions with serum bicarbonate <22 mmol/L, likely due to SZC-binding of gastrointestinal ammonium. These SZC-induced serum bicarbonate increases occurred regardless of CKD stage and were sustained during ongoing maintenance therapy.
Identifiants
pubmed: 32588050
pii: 5862972
doi: 10.1093/ndt/gfaa158
pmc: PMC8075377
doi:
Substances chimiques
Bicarbonates
0
Silicates
0
Sodium Bicarbonate
8MDF5V39QO
Urea
8W8T17847W
sodium zirconium cyclosilicate
D652ZWF066
Potassium
RWP5GA015D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
871-883Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
Références
Nephrol Dial Transplant. 2009 Apr;24(4):1232-7
pubmed: 19015169
J Am Soc Nephrol. 2009 Feb;20(2):251-4
pubmed: 19193780
J Nephrol. 2019 Dec;32(6):989-1001
pubmed: 31598912
Am J Kidney Dis. 2014 Oct;64(4):534-41
pubmed: 24953891
Kidney Int. 2013 Feb;83(2):308-15
pubmed: 22992469
Kidney Int. 1989 Dec;36(6):1112-8
pubmed: 2557481
Expert Opin Pharmacother. 2015;16(11):1727-34
pubmed: 26159448
Clin J Am Soc Nephrol. 2019 Jun 7;14(6):798-809
pubmed: 31110051
Clin J Am Soc Nephrol. 2019 Jul 5;14(7):1011-1020
pubmed: 31196951
Kidney Int. 2018 Feb;93(2):390-402
pubmed: 29054531
JAMA Intern Med. 2019 Nov 1;179(11):1600-1601
pubmed: 31682699
J Clin Med. 2019 Feb 07;8(2):
pubmed: 30736428
N Engl J Med. 2015 Jan 15;372(3):222-31
pubmed: 25415807
ESC Heart Fail. 2020 Feb;7(1):54-64
pubmed: 31944628
Am J Nephrol. 2019;50(6):473-480
pubmed: 31658466
Nephrol Dial Transplant. 2021 Jan 1;36(1):137-150
pubmed: 32030422
Kidney Int. 2015 Aug;88(2):404-11
pubmed: 25651363
PLoS One. 2014 Dec 22;9(12):e114686
pubmed: 25531770
Lancet. 2019 Apr 6;393(10179):1417-1427
pubmed: 30857647
J Am Soc Nephrol. 2009 Sep;20(9):2075-84
pubmed: 19608703
Kidney Int. 2014 Nov;86(5):1031-8
pubmed: 24694986
Nephron. 2018;138(3):222-228
pubmed: 29050011
Am J Kidney Dis. 2013 Oct;62(4):670-8
pubmed: 23489677
Physiol Rev. 2017 Apr;97(2):465-494
pubmed: 28151423
Rev Cardiovasc Med. 2015;16(2):140-55
pubmed: 26198561
N Engl J Med. 2015 Jan 15;372(3):211-21
pubmed: 25415805
Am J Kidney Dis. 2014 Oct;64(4):542-9
pubmed: 24953890
JAMA. 2014 Dec 3;312(21):2223-33
pubmed: 25402495
Kidney Int Suppl (2011). 2017 Dec;7(3):e1
pubmed: 30681074